$1.58
+0.01 (+0.64%)
Open$1.59
Previous Close$1.57
Day High$1.60
Day Low$1.52
52W High$5.48
52W Low$0.88
Volume—
Avg Volume142.7K
Market Cap38.73M
P/E Ratio—
EPS$-0.42
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,463.3% upside
Current
$1.58
$1.58
Target
$24.70
$24.70
$17.28
$24.70 avg
$43.03
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.17M | 1.04M | 9.21M |
| Net Income | -11,243,139 | -9,012,134 | 1.19M |
| Profit Margin | -962.1% | -914.0% | 12.9% |
| EBITDA | -9,709,254 | -8,214,990 | 1.73M |
| Free Cash Flow | — | — | 900.3K |
| Rev Growth | +12.3% | +12.3% | -0.3% |
| Debt/Equity | 1.46 | 1.46 | 0.87 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |